Middle-aged women are more likely to be diagnosed with late-stage lung cancer than older patients, suggest findings of a new analysis by Cancer Research UK.
News
NHS innovation competition winners unveiled
Health Enterprise East has unveiled the winners of its NHS innovation competition which, for the first time, included a new category that opened the door to industry participants.
Laser surgery for BPH could save NHS £3.2m
NICE is supporting use of Boston Scientific’s laser therapy GreenLight XPS to treat benign prostatic hyperplasia, which could improve outcomes for patients and save the NHS a substantial chunk of cash.
Health and social care leaders call for faster service integration
Experts are warning that the integration of health and social care – which has been a key policy theme for many years – is now at risk because of mounting pressures on services.
Shire picks up two breakthrough badges for rare disease drugs
US regulators have awarded ‘Breakthrough Therapy’ badges to two investigational products being developed by Shire: a novel formulation of budesonide for eosinophilic esophagitis and maralixibat for progressive familial intrahepatic cholestasis type 2.
Teva halts sales of migraine patch on reports of burns, scars
Teva Pharmaceutical Industries has suspended sales of its migraine patch Zecuity following post-marketing reports of burns and scars in patients.
Roche bags Eleven’s experimental eye disease drug
Roche has snapped up rights to an experimental eye disease drug and technology from US biotech Eleven Biotherapeutics in a deal that be worth $270 million.
Trial shows heart benefits of Novo’s diabetes drug Victoza
New data on Novo Nordisk’s diabetes therapy Victoza show that the drug significantly cut the risk of major cardiovascular events and death in adults with type II diabetes.
Four new medicines OK’d for use by NHS Scotland
Cost regulators have approved the use of four new medicines for use by NHS Scotland, including a new option for Parkinson’s disease and asthma, but rejected Sanofi-Genzyme’s Jevtana for prostate cancer and Amgen’s Repatha for high cholesterol.
Novartis’ Jakavi comes out on top in rare blood cancer trial
New data shows Novartis’ Jakavi to be superior than best available therapy in patients with the rare haematological cancer polycythemia vera (PV), which affects around 100,000 people globally a year.
Shire completes EU decentralisation procedure for Cuvitru
Shire’s Cuvitru is a big step closer to a roll-out in Europe having completed the decentralised procedure supporting its approval for primary and certain secondary immunodeficiency disorders.
Cervical cancer cases to rise sharply in the elderly, charity warns
The incidence of cervical cancer in women aged over 50 will increase sharply if current screening trends continue, a UK charity is warning.
Sanofi’s new diabetes combo hits PhIII targets
A new diabetes combination therapy being developed by Sanofi has hit targets in two pivotal Phase III studies, showing a superior reduction in blood glucose compared to insulin glargine and versus lixisenatide.
AZ sells anaesthetics portfolio to Aspen
AstraZeneca is selling rights to its global anaesthetics portfolio outside the US to Aspen Global Inc (AGI) in a deal that could be worth $770 million.
Amgen/Novartis migraine drug shows promise in trial
An experimental therapy being developed by Amgen and Novartis to prevent chronic migraine has hit its primary targets, confirming safety and efficacy in patients over the 12-week treatment period.
